CoChat

HMGA2 Regulates Transcription of the Imp2 Gene via an Intronic Regulatory Element in Cooperation with Nuclear Factor-κB

Cleynen, Isabelle, Brants, Jan R., Peeters, Kristel, Deckers, Rob, Debiec-Rychter, Maria, Sciot, Raf, Van de Ven, Wim J.M., Petit, Marleen M.R. · 2007 · Molecular Cancer Research
Cited by 92

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

IMP2 (insulin-like growth factor-II mRNA binding protein 2) is an oncofetal protein that is aberrantly expressed in several types of cancer. We recently identified the Imp2 gene as a target gene of the architectural transcription factor HMGA2 (high mobility group A2) and its tumor-specific truncated form HMGA2Tr. In this study, we investigated the mechanism via which HMGA2 regulates Imp2 gene expression. We show that HMGA2 and HMGA2Tr directly regulate transcription of the Imp2 gene by binding to an AT-rich regulatory region located in the first intron. In reporter experiments, we show that this AT-rich regulatory region mimics the response of the endogenous Imp2 gene to HMGA2 and HMGA2Tr. Furthermore, we show that a consensus nuclear factor-κB (NF-κB) binding site located immediately adjacent to the AT-rich regulatory region binds NF-κB and that NF-κB and HMGA2 cooperate to regulate Imp2 gene expression. Finally, we provide evidence that there is a strong and statistically significant correlation between HMGA2 and IMP2 gene expression in human liposarcomas. (Mol Cancer Res 2007;5(4):363–72)

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-06-0331

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 42

  1. Leeds P, Kren BT, Boylan JM, et al. Developmental regulation of CRD-BP, an RNA-binding protein that stabilizes c-myc mRNA in vitro. Oncogene 1997;14:1279–86. · DOI
  2. Mori H, Sakakibara S, Imai T, et al. Expression of mouse igf2 mRNA-binding protein 3 and its implications for the developing central nervous system. J Neurosci Res 2001;64:132–43. · DOI · Paper page
  3. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14:2729–33. · DOI · Paper page
  4. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 2002;287:49–54. · DOI · Paper page
  5. Yisraeli JK. VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell 2005;97:87–96. · DOI · Paper page
  6. Lu M, Nakamura RM, Dent ED, et al. Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol 2001;159:945–53. · DOI
  7. Zhang JY, Chan EK, Peng XX, et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 2001;100:149–56. · DOI
  8. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120–6.
  9. Brants JR, Ayoubi TA, Chada K, Marchal K, Van de Ven WJ, Petit MM. Differential regulation of the insulin-like growth factor II mRNA-binding protein genes by architectural transcription factor HMGA2. FEBS Lett 2004;569:277–83. · DOI · Paper page
  10. Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. The expression pattern of the Hmgic gene during development. Genes Chromosomes Cancer 1998;23:350–7. · doi:10.1002/(sici)1098-2264(199812)23:4<350::aid-gcc10>3.0.co;2-e
  11. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13:2439–46.
  12. Zhou X, Benson KF, Przybysz K, et al. Genomic structure and expression of the murine Hmgi-c gene. Nucleic Acids Res 1996;24:4071–7. · DOI
  13. Hess JL. Chromosomal translocations in benign tumors: the HMGI proteins. Am J Clin Pathol 1998;109:251–61. · doi:10.1093/ajcp/109.3.251
  14. Tallini G, Dal Cin P. HMGI(Y) and HMGI-C dysregulation: a common occurrence in human tumors. Adv Anat Pathol 1999;6:237–46. · DOI · Paper page
  15. Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 1996;54:35–100. · DOI · Paper page
  16. Ashar HR, Fejzo MS, Tkachenko A, et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 1995;82:57–65. · DOI · Paper page
  17. Kools PF, Wanschura S, Schoenmakers EF, et al. Identification of the chromosome 12 translocation breakpoint region of a pleomorphic salivary gland adenoma with t(1;12)(p22;q15) as the sole cytogenetic abnormality. Cancer Genet Cytogenet 1995;79:1–7. · doi:10.1016/0165-4608(94)00137-z
  18. Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Res 2002;12:996–1006. · DOI · Paper page
  19. Noro B, Licheri B, Sgarra R, et al. Molecular dissection of the architectural transcription factor HMGA2. Biochemistry 2003;42:4569–77. · DOI
  20. Borrmann L, Schwanbeck R, Heyduk T, et al. High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucleic Acids Res 2003;31:6841–51. · DOI
  21. Arrigoni G, Doglioni C. Atypical lipomatous tumor: molecular characterization. Curr Opin Oncol 2004;16:355–8. · doi:10.1097/01.cco.0000127878.85125.53
  22. Dei Tos AP, Doglioni C, Piccinin S, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000;190:531–6. · DOI · Paper page
  23. Forus A, Larramendy ML, Meza-Zepeda LA, et al. Dedifferentiation of a well-differentiated liposarcoma to a highly malignant metastatic osteosarcoma: amplification of 12q14 at all stages and gain of 1q22-q24 associated with metastases. Cancer Genet Cytogenet 2001;125:100–11. · DOI
  24. Tallini G, Dal Cin P, Rhoden KJ, et al. Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol 1997;151:37–43.
  25. Trahan S, Erickson-Johnson MR, Rodriguez F, et al. Formation of the 12q14-q15 amplicon precedes the development of a well-differentiated liposarcoma arising from a nonchondroid pulmonary hamartoma. Am J Surg Pathol 2006;30:1326–9. · doi:10.1097/01.pas.0000213257.69478.2f
  26. Pentimalli F, Dentice M, Fedele M, et al. Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. Cancer Res 2003;63:7423–7.
  27. Aman P, Ron D, Mandahl N, et al. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 1992;5:278–85. · DOI · Paper page
  28. Crozat A, Aman P, Mandahl N, Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993;363:640–4. · DOI · Paper page
  29. Rabbitts TH, Forster A, Larson R, Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993;4:175–80. · DOI · Paper page
  30. Turc-Carel C, Limon J, Dal Cin P, Rao U, Karakousis C, Sandberg AA. Cytogenetic studies of adipose tissue tumors. II. Recurrent reciprocal translocation t(12;16)(q13;p11) in myxoid liposarcomas. Cancer Genet Cytogenet 1986;23:291–9. · DOI · Paper page
  31. Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001;1519:13–29. · DOI · Paper page
  32. Yie J, Merika M, Munshi N, Chen G, Thanos D. The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J 1999;18:3074–89. · DOI · Paper page
  33. Fedele M, Visone R, De Martino I, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006;9:459–71. · DOI · Paper page
  34. Tessari MA, Gostissa M, Altamura S, et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol 2003;23:9104–16. · DOI · Paper page
  35. Bagga R, Michalowski S, Sabnis R, Griffith JD, Emerson BM. HMG I/Y regulates long-range enhancer-dependent transcription on DNA and chromatin by changes in DNA topology. Nucleic Acids Res 2000;28:2541–50. · DOI
  36. Reeves R. HMGA proteins: flexibility finds a nuclear niche? Biochem Cell Biol 2003;81:185–95. · DOI
  37. Mantovani F, Covaceuszach S, Rustighi A, et al. NF-κB mediated transcriptional activation is enhanced by the architectural factor HMGI-C. Nucleic Acids Res 1998;26:1433–9. · DOI
  38. Moynagh PN. The NF-κB pathway. J Cell Sci 2005;118:4589–92. · DOI · Paper page
  39. Crombez KR, Vanoirbeek EM, Van de Ven WJ, Petit MM. Transactivation functions of the tumor-specific HMGA2/LPP fusion protein are augmented by wild-type HMGA2. Mol Cancer Res 2005;3:63–70. · DOI
  40. Sambrook J, Russell DW. Molecular Cloning: a Laboratory Manual. 3rd. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2001.
  41. Wadman IA, Osada H, Grutz GG, et al. The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 1997;16:3145–57. · DOI · Paper page
  42. Polito P, Dal Cin P, Debiec-Rychter M, Hagemeijer A. Human solid tumors: cytogenetic techniques. Methods Mol Biol 2003;220:135–50. · doi:10.1385/1-59259-363-1:135

Cited by

See all 92

Metadata

Authors
Cleynen, I., Brants, J. R., Peeters, K., Deckers, R., Debiec-Rychter, M., Sciot, R., Van de Ven, W. J. M., & Petit, M. M. R.
Venue
Molecular Cancer Research
Published
2007-04-01
Volume
5
Issue
4
Pages
363-372
ISSN
  • 1541-7786 (ISSN-L)
  • 1557-3125
OpenAlex
W2162324253
Cited by
92
References
3
FWCI
1.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HMGA2 Regulates Transcription of the Imp2 Gene via an Intronic Regulatory Element in Cooperation with Nuclear Factor-κB. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-06-0331
The paper
Cleynen, I., Brants, J. R., Peeters, K., Deckers, R., Debiec-Rychter, M., Sciot, R., Van de Ven, W. J. M., & Petit, M. M. R. (2007). HMGA2 Regulates Transcription of the Imp2 Gene via an Intronic Regulatory Element in Cooperation with Nuclear Factor-κB. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-06-0331

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.